Rank #1711VRDN

Viridian Therapeutics, Inc.

$28.10

-0.04% (Daily)

Market Cap

$2.68B

Revenue

$70.79M

Rank by MCap

#1711

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Stephen F. Mahoney J.D., MBA

Headquarters

Waltham, MA

Employees

143

About Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for ...